Vanda Pharmaceuticals VNDA
-
2 Pharmaceutical Companies Trading Below Net Cash
By Markus Aarnio : Since my last article in February about Myrexis ( MYRX ) we have seen a small pop in the share price and a subsequent drop as well. The pop was due to a press release given on February 15th stating that company's Board of Directors has retained Stifel Nicolaus Weisel, an ...
-
New Morningstar Analyst Report - Vanda Pharmaceuticals , Inc.
… management's view of Vanda's future, in our opinion. Vanda Pharmaceuticals focuses on the development and commercialization of therapies ..... back from the dead to win marketing approval. Although Vanda Pharmaceuticals will have to face off against well-entrenched competitors …
-
Vanda Sees Good Fanapt Growth in 1Q, but Higher Cost Projections Will Hasten Cash Burn for 2012
In its first-quarter results, Vanda Pharmaceuticals VNDA reported sales of Fanapt that came in slightly above our expectations. However, the company's projections for higher full …
-
Eli Lilly: 5% Dividend With A Chance For Capital Gains
By Alexander J. Poulos : Conservative income investors have seen their interest payments decline as the world continues to be ravaged by the global financial crisis. Interest earned on money markets and CDs, once a favored vehicle for retirees, now pay in many instances less than 1%. The U.S. ...
-
UPDATE 1-Vanda buys Lilly's experimental drug
April 16 (Reuters) - Vanda Pharmaceuticals Inc said it acquired from Eli Lilly the worldwide development and commercialization rights of a molecule for the treatment of several indications, including...
-
16 Biotech Stocks Sold Off By Hedge Funds
By Kapitall : Do you like to follow the stocks the smart money is buying? If so, you may also be interested in the stocks they're selling. We ran a screen on the biotech industry for stocks with bearish sentiment from institutional investors (such as hedge funds) with significant net institutional
-
Vanda Pharmaceuticals Trading Below Net Cash
By Markus Aarnio : Vanda Pharmaceuticals ( VNDA ) is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders …
-
Vanda Advances Key Pipeline Drug in 4Q, but Faces Potential Delay in European Launch of Fanapt
Vanda VNDA reported fourth-quarter earnings that fell fairly close to our expectations, and we do not anticipate any major changes to our …
-
Vanda Pharmaceuticals ( VNDA ): Q4 EPS of -$0.20 misses by $0.01. Revenue of $8.2M (+5.2% Y/Y) in-line. (PR)
Vanda Pharma ( VNDA ): Q4 EPS of -$0.20 misses by $0.01 . Revenue of $8.2M (+5.2% Y/Y) in-line. ( PR ) Post your comment!
-
6 Highly Liquid Biotech Stocks With Positive Correlation To Volatility
By Kapitall : Do you think the stock market is in for a new bout of volatility? If so, you may be interested in this list. We ran a screen on the biotech industry for stocks with high liquidity, measured by current ratios above 3. Because biotech companies often operate for expanded periods of time